Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Oligodendroglioma 1Neurofibrosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hepatoblastoma 1Gliosarcoma 1Glioma 1Glioblastoma 1Ependymoma 1Dermatofibrosarcoma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Doxorubicin 19Ifosfamide 12Radiotherapy 11pembrolizumab 6Nivolumab 6Ipilimumab 6pazopanib 4Specimen Handling 4Radiation 4Gemcitabine 4Docetaxel 4CTLA-4 Antigen 4Biopsy 4Trabectedin 3Sunitinib 3Magnetic Resonance Spectroscopy 3pegfilgrastim 2liposomal doxorubicin 2cabozantinib 2brostallicin 2X-Rays 2Radiotherapy, Conformal 2Radiation Dose Hypofractionation 2Methotrexate 2Imatinib Mesylate 2Filgrastim 2Etoposide 2Diathermy 2Cisplatin 2Chemotherapy, Adjuvant 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Histiocytoma, Malignant Fibrous × MLN 8237 × Sarcoma × Clear all
NCT01653028 2017-11-30

Alisertib in Treating Patients With Advanced or Metastatic Sarcoma

National Cancer Institute (NCI)

Phase 2 Completed
72 enrolled 13 charts
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Dermatofibrosarcoma, Neurofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡